Precigen, Inc.
- Jurisdiction
United States - LEI
549300XCWNQU35K64G19 - ISIN
US74017N1054 (PGEN )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
4
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
4
/ 7
Profile
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. Read full profile
Fundamentals
- Net revenue
€3.70M - Gross margin
-8.0% - EBIT
-€85.49M - EBIT margin
-2,309.5% - Net income
-€106.19M - Net margin
-2,868.7%
Statement period: - (published )
Estimates
| Fiscal Year | Net revenue | Net income |
|---|---|---|
|
|
| |
|
|
| |
|
|
|
Stock price
Dividends
No dividend payouts
Analyst ratings
No analyst ratings available
Insider Transactions
| Name | Title | Transaction Date | Shares | Price | Value |
|---|---|---|---|---|---|
| AGEE NANCY H | N/A |
|
|
|
|
| AGEE NANCY H | N/A |
|
|
|
|
Earnings Calls
Investor transactions
| Name | Shares | Value | Last change | Change type |
|---|---|---|---|---|
| Samantha McLemore |
|
|
|
Sell |
| Peter Brown |
|
|
|
Sell |
Earnings Calls
Latest earnings call: March 19, 2024 (Q4 2023)